Please assess the completion status of the following clinical trial:

Trial Title: Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18 years or older, with histologically or cytologically-confirmed either:~  1. Chemo-refractory DLBCL (including transformed low grade lymphoma)~ 2. Lenalidomide naïve; relapsed or refractory CD20-positive follicular lymphoma (Grade 1, 2, or 3a) following at least one prior standard systemic treatment regimen including systemic chemo-, immune-; or chemo-immunotherapy and at least one prior line of salvage therapy with no prior exposure to lenalidomide, or double-refractory FL participants with no prior exposure to lenalidomide (FL-1 cohort)~ 3. Lenalidomide exposed: relapsed or refractory CD20-positive follicular lymphoma (Grade 1, 2, or 3a) previously treated with at least two cycles of lenalidomide-containing regimen (FL-2 cohort), either as a single agent or in combination~* At least one site of measurable disease~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.~* Participants must have the following laboratory values:~* Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L or ≥ 1.0 x 109/L (with bone marrow involvement with DLBCL)~* Hemoglobin (Hgb) ≥ 8 g/dL.~* Potassium within normal limits~* Asparate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) and Alanine Aminotransferase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 X ULN if liver tumor is present.~* Serum bilirubin ≤ 1.5 x ULN.~* Estimated serum creatinine clearance of ≥ 50 mL/min~* Participants must have the following laboratory values:~Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L without growth factor support for 7 days (14 days if participants received pegfilgrastim).~* Males enrolled into treatment arms receiving CC-122 must: Agree to abstain from donating sperm while taking IP and for at least 95 days following discontinuation of IP~Exclusion Criteria:~* Symptomatic central nervous system involvement.~* Known symptomatic acute or chronic pancreatitis.~* Persistent diarrhea or malabsorption despite medical management.~* Peripheral neuropathy ≥ grade 2~* Impaired cardiac function or clinically significant cardiac diseases~* Participants with diabetes on active treatment (for participants treated on CC-223 containing arms only)~* Prior autologous stem cell transplant (ASCT) ≤ 3 months before first dose.~* Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning.~* Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks prior to starting study drugs, whichever is shorter.~* Participants who have undergone major surgery ≤ 2 weeks prior to starting study drugs.~* Women who are pregnant or breast feeding. Adults of reproductive potential not willing to employ two forms of birth control.~* Participants with known HIV infection, chronic active hepatitis B or C virus (HBV/HCV) infection.~* Participants with treatment-related myelodysplastic syndrome.~* History of concurrent second cancers requiring active, ongoing systemic treatment.~* Prior treatment with a dual mTORC1/mTORC2 inhibitor (CC-223 arms only) or BTK inhibitor (PCI-32765) (CC-292 arms only). \[Prior treatment with rapamycin analogues, PI3K or AKT inhibitors, lenalidomide and rituximab are allowed\].

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CC-122 + CC-223 +/- rituximab (Type: EXPERIMENTAL): CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
- CC-122 + CC-292 +/- rituximab (Type: EXPERIMENTAL): CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days
- CC-292 + CC-223 +/- rituximab (Type: EXPERIMENTAL): CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
- CC-122 + rituximab (Type: EXPERIMENTAL): CC-122 administered orally once daily in combination with Rituximab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy